Abstract
IntroductionAllergic rhinitis is a chronic inflammatory disease which affects 1 out of 6 individuals. Perennial allergic rhinitis accounts for 40% of AR cases. Ciclesonide is one of the relatively new intranasal steroid for allergic rhinitis. ObjectiveThe purpose of this study was to evaluate the efficacy and safety of ciclesonide in the treatment of perennial allergic rhinitis. MethodsWe searched Pubmed, Scientific Citation Index, Embase, Clinical Trial Registries for randomized controlled trials and Cochrane Central Register of Controlled Trials to find out the randomized controlled Trial comparing ciclesonide with placebo for PAR. ResultsEight studies were included. In comparison with placebo groups, ciclesonide groups significantly decreased Reflective Total Nasal Symptom Score (MD=−0.56; 95% CI −0.72 to 0.39, p<0.00001) with heterogeneity (p=0.19, I2=24%), Instantaneous Total Nasal Symptom Score (MD=−0.57; 95% CI −0.75 to −0.39, p<0.00001) with heterogeneity (p=0.34, I2=11%). A significant effect for Reflective Nasal Symptom Score Subtotal (MD=−0.15; 95% CI −0.18 to −0.13, p<0.00001) with heterogeneity (p=0.12, I2=24%) was also demonstrated. Rhinoconjunctivitis quality of life questionnaire score (RQLQs) (MD=−0.27; 95% CI −0.39 to −0.15, p<0.00001) with heterogeneity (p=0.58, I2=0%) in the treatment of ciclesonide was also significantly reduced. In addition, the difference in Treatment-Emergent Adverse Events between the two groups was not significant. ConclusionCiclesonide can improve perennial allergic rhinitis without increasing adverse events. Ciclesonide may be another valuable choice for perennial allergic rhinitis in the future.
Highlights
Allergic rhinitis is a chronic inflammatory disease which affects 1 out of 6 individuals
The symptoms of Allergic Rhinitis (AR) interfere with all aspects of daily life that are associated with decreased sleep quality and performance at work.[2]
In the initial search 53 related publications were identified in total. 14 duplicates were removed afterward. 29 studies were excluded by reading the title or abstract
Summary
Allergic rhinitis is a chronic inflammatory disease which affects 1 out of 6 individuals. Objective: The purpose of this study was to evaluate the efficacy and safety of ciclesonide in the treatment of perennial allergic rhinitis. Rhinoconjunctivitis quality of life questionnaire score (RQLQs) (MD = −0.27; 95% CI −0.39 to −0.15, p < 0.00001) with heterogeneity (p = 0.58, I2 = 0%) in the treatment of ciclesonide was significantly reduced. Allergic Rhinitis (AR), a chronic inflammatory disease, is characterized by nasal itching, sneezing, runny nose and congestion.[1] As a highly prevalent condition, AR affects 1 out of 6 individuals. Despite currently available treatment options, the incidence of AR is increasing It remains the leading cause of morbidity, absenteeism and restricted activities and is related to considerable cost pressures in the health care system.[3,4] AR can be divided into seasonal and perennial forms. AR is a Type 1 IgE-mediated hypersensitivity reaction.[6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
